Jolanta Krajewska

The Maria Sklodowska-Curie National Research Institute of Oncology

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Barbara Jarząb

The Maria Sklodowska-Curie National Research Institute of Oncology

100

Agnieszka Czarniecka

The Maria Sklodowska-Curie National Research Institute of Oncology

Daria Handkiewicz-Junak

The Maria Sklodowska-Curie National Research Institute of Oncology

Aleksandra Kukulska

State Higher Vocational School in Głogów

Małgorzata Oczko‐Wojciechowska

The Maria Sklodowska-Curie National Research Institute of Oncology

Michał Jarząb

The Maria Sklodowska-Curie National Research Institute of Oncology

Dagmara Rusinek

The Maria Sklodowska-Curie National Research Institute of Oncology

Ewa Chmielik

The Maria Sklodowska-Curie National Research Institute of Oncology

Józef Roskosz

The Maria Sklodowska-Curie National Research Institute of Oncology

Kornelia Hasse-Lazar

The Maria Sklodowska-Curie National Research Institute of Oncology

Cooperative Institutions

The Maria Sklodowska-Curie National Research Institute of Oncology

127

Centrum Onkologii

Medical University of Silesia

National Institute of Oncology

Polish Academy of Sciences

Inserm

Górnośląskie Centrum Medyczne

Exelixis (United States)

University of Silesia in Katowice

Medical University of Warsaw

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Emerging multikinase inhibitors for the treatment of differentiated thyroid cancer: whom to treat?

Translational Cancer Research (2016)

Jolanta Krajewska Dagmara Rusinek Barbara Jarząb

Thyroid cancer (TC) is the most common endocrine malignancy, showing a rapid growth in its incidence during recent years. In 2013 the predicted number of all people with TC living in the USA was nearly 637,000, whereas estimated number of new cases diagnosed in 2016 is about 64,300. TC accounts for ~3.8% of all new cancer cases, but—due to a generally good prognosis—in 2016 this disease will count for no more than 2000 deaths (0.3% of all cancer mortality) (1).

10.21037/11289

Cite

Citations (0)

Treatment with sorafenib in advanced thyroid cancer - a case report.

Endokrynologia Polska (2010)

Jolanta Krajewska Tomasz Olczyk Józef Roskosz Ewa Paliczk-Cieślik Aleksandra Kukulska Anetta Smietana

Papillary thyroid cancer (PTC) usually has a good prognosis. The treatment, including total thyroidectomy and complementary radioiodine (RAI) therapy, gives complete remission in 90% of patients. However, in 10% of subjects with metastatic disease, the prognosis is poor. In the group of patients with disease progression and no 131I uptake, searching for new therapeutic modalities before all tyrosine kinase inhibitors and other antiangiogenic agents is necessary. The study presents the case of a 55-year-old male with advanced PTC /pT3mNxMo/ diagnosed in 1993. Primary treatment by total thyroidectomy and 131I ablation led to complete remission. In 2000 local as well as lymph node recurrence was diagnosed and successively treated by surgery. In 2006 an increasing serum thyroglobulin level was noted and a single lung metastasis was diagnosed and operated on. In 2007 new foci in CNS and vertebral column with no 131I uptake were stated. Further progression (bones, CNS, and pterygoid muscle) was confirmed by PET-CT. The patient underwent neurosurgical metastasectomy twice and palliative CNS and vertebra's radiotherapy. Liver metastases were diagnosed in 2009. Treatment with increasing doses of thalidomide (up to 800 mg/d) was administered for 3 months with a good tolerance; however, the therapy was withdrawn due to cancer progression. Next, sorafenib (800 mg/d) was given for 16 weeks. Radiological examination performed after 16 weeks confirmed stable disease, whereas 2 months later, after sorafenib withdrawal due to lack of treatment possibility, further progression was observed. Metronomic chemotherapy with Adriamycin was instituted which gave disease stabilization for 6 months. The patient died with advanced disseminated disease due to pulmonary embolism. We present this case to document no adverse effects of therapy with sorafenib in a patient with brain DTC metastases. Sorafenib therapy was only short-term, but no progression occurred in this time.

Source

Cite

Citations (12)

Emerging multikinase inhibitors for the treatment of differentiated thyroid cancer: whom to treat?

Translational Cancer Research (2016)

Jolanta Krajewska Dagmara Rusinek Barbara Jarząb

Cancer Treatment

10.21037/tcr.2016.12.20

Cite

Citations (1)

Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study

The Lancet Diabetes & Endocrinology (2019)

Fréderic Castinetti Steven G. Waguespack Andreas Machens Shinya Uchino Kornelia Hasse-Lazar

Medullary carcinoma

Penetrance

10.1016/s2213-8587(18)30336-x

Cite

Citations (119)

Author Index Vol. 153, 2010

International Archives of Allergy and Immunology (2010)

G. Lund Henrik H. Jacobi Per Stahl Skov Jens‐Christian Holm Kaare Lund

10.1159/000322705

Cite

Citations (0)

Occurrence of BRAF mutations in a Polish cohort of PTC patients - preliminary results.

PubMed (2010)

Agnieszka Czarniecka Dagmara Rusinek Ewa Stobiecka Jolanta Krajewska Monika Kowal

Genetic alterations involving the mitogen-activated protein kinase (MAPK) pathway are frequently demonstrated in papillary thyroid cancer (PTC). BRAF(V600E), the most frequent mutation in adult patients, is present in approximately 50% of PTC. Most clinical studies have demonstrated an association of BRAF(V600E) mutation with aggressive clinicopathological characteristics and high tumour recurrence, although the results are controversial. In this study we present the preliminary results of BRAF mutation frequence in a group of 88 Polish patients with papillary thyroid cancer (PTC) and relate it to the outcome all DTC patients operated in 2004 and 2005. BRAF (V600E) mutation was diagnosed in 38 (43%) of cases.The presence of BRAF mutation was evaluated in 88 PTC tumours. DNA was isolated from tissue parafin blocks, and the mutation V600E was evaluated by sequence analysis with an AbiPrism 377 and 3130 xl genetic analyzer (Life Technologies). Statistical analysis was carried out with the use of SPSS 12 software. The chi² and Kaplan-Meyer survival analysis were performed.From all analyzed clinico-pathological factors, only older age positively correlated with BRAF mutation frequency (p = 0.0017). Lymph node/distant metastases, multifocality, and extra-thyroid extension did not correlate with BRAF status. One cancer related death and two reccurences were observed in the BRAF+ group while one relapse was diagnosed in the BRAF- group.Although many studies document BRAF mutation as a prognostic factor in PTC our results underline that it is too early to consider it as a routine clinical predictive factor.

V600E

Mutation Testing

Source

Cite

Citations (18)

Clinical genetic of medullary thyroid carcinoma

Postępy Nauk Medycznych (2015)

Barbara Jarząb Jolanta Krajewska Jan Włoch Zbigniew Wygoda

Medullary carcinoma

Source

Cite

Citations (1)

Urinary iodine in patients with differentiated thyroid cancer (DTC) during L-thyroxine treatment.

Endokrynologia Polska (2010)

Barbara Michalik Józef Roskosz Anita Stanjek-Cichoracka Jolanta Krajewska Michał Kalemba

Urinary iodine concentrations were analyzed in the morning urine samples of patients with differentiated thyroid cancer (DTC).The analyzed group included 572 DTC patients who were treated with radioiodine or hospitalized for evaluation of radioiodine treatment effects in 2009 at the Institute of Oncology in Gliwice. Ioduria was analyzed by PAMM (Program Against Micronutrient Malnutrition) method before rhTSH administration. A total of 545 tests were performed during L-thyroxine treatment and 27 after L-thyroxine withdrawal.Median L-thyroxine dose was 150 μg/day. Median ioduria was 127.5 μg/L during L-thyroxine therapy and 134 μg/L after the L-thyroxine withdrawal. No distinct relation between ioduria and L-thyroxine dose was observed. Ioduria < 200 μg/L was observed in over 90% of patients and this cut-off was chosen for the reference range. Only 1.2% of patients showed a distinct stable iodine contamination (ioduria ≥ 300 μg/L).Urinary iodine concentrations in differentiated thyroid cancer patients treated with L-thyroxine vary in a wide range and do not show a clear relation with L-thyroxine dose.

Source

Cite

Citations (1)

The role of FDG-PET in localization of recurrent lesions of differentiated thyroid cancer (DTC) in patients with asymptomatic hyperthyroglobulinemia in a real clinical practice

European Journal of Endocrinology (2016)

Aleksandra Kukulska Jolanta Krajewska Zofia Kołosza E Paliczka-Cies ́lik Zbigniew Puch

Available methods, including serum thyroglobulin (Tg) measurement and whole-body scan (WBS) performed after radioiodine administration, allow for a precise diagnostics in differentiated thyroid cancer (DTC). However, some asymptomatic patients demonstrate negative WBS despite a high Tg serum concentration. In these subjects, fluorodeoxyglucose-positron emission tomography (FDG-PET) should be considered. The primary aim of our study was to evaluate a diagnostic value of FDG-PET in asymptomatic hyperthyroglobulinemia. The secondary one was to determine a prognostic value of a negative FDG-PET result in DTC patients with elevated Tg level.One hundred and ten FDG-PET/CT scans were retrospectively analyzed, 85 scans were done under TSH stimulation and 25 on LT4 suppressive therapy. Follow-up ranged between 4 and 9 years.The first FDG-PET/CT detected cancer foci in 49 subjects with a global sensitivity of 45%. When the sensitivity was evaluated with reference to TSH stimulation and suppression, its values were 50 and 28% respectively. In 42 patients, FDG-PET failed to diagnose the reason for elevated Tg level. During further follow-up, in 17 of them, DTC recurrence was detected by other methods (CT, MRI, US). Fourteen subjects with asymptomatic hyperthyroglobulinemia were free of DTC progression for at least 4 years.FDG-PET in DTC patients with asymptomatic hyperthyroglobulinemia constitutes a valuable diagnostic tool. Negative FDG-PET demonstrated a limited prognostic significance, as only every third patient did not show DTC progression. Moreover, negative FDG-PET does not justify less strict DTC monitoring, because it is related to 40% risk of relapse during the 5-year follow-up.

Clinical Practice

10.1530/eje-16-0360

Cite

Citations (12)

Management of treatment-related toxicity caused by multi kinase inhibitors administered due to advanced thyroid carcinoma

Endocrine Abstracts (2017)

Jolanta Krajewska Aleksandra Kukulska Daria Handkiewicz-Junak Ewa Paliczka-Cieślik Tomasz Olczyk

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

10.1530/endoabs.49.ep1440

Cite

Citations (0)